Guy C. Toner

Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma.

Carole A. Harris, Danka Sinikovic Zebic, Michelle Frances Morris, Tom Ferguson et autres

au (code pays fourni par la source)

Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma

Carole A. Harris, Danka Sinikovic Zebic, M. Morrison, Tom Ferguson et autres

au (code pays fourni par la source)

The utility of genomics and functional imaging to predict sunitinib pharmacokinetics and pharmacodynamics: The predict SU study

Michael Michael, Guy C. Toner, Vinod Ganju, E. Link et autres

au (code pays fourni par la source)

1886P Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)

Craig Gedye, Carole A. Harris, Martin R. Stockler, Michelle Frances Morris et autres

au, us (code pays fourni par la source)

The Utility of Genomics and Functional Imaging to Predict Sunitinib Pharmacokinetics and Pharmacodynamics: The Predict Su Study

Michael Michael, Guy C. Toner, Vinod Ganju, Emma Link et autres

au (code pays fourni par la source)

Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations

Ciara Conduit, Jeremy Lewin, Andrew Weickhardt, James Lynam et autres

au (code pays fourni par la source)

Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up

Ciara Conduit, Thuan Tzen Koh, Michael S. Hofman, Guy C. Toner et autres

au (code pays fourni par la source)

High‐dose chemotherapy for relapsed germ cell tumours: outcomes in low‐volume specialized centres

Elizabeth A. Connolly, Andrew Weickhardt, Peter Grimison, Rebecca Asher et autres

au, nz (code pays fourni par la source)

Clinical utility of FDG PET-CT in stage 1 and advanced testicular seminoma.

Ciara Conduit, Michael S. Hofman, Jeremy Lewin, Guy C. Toner et autres

au (code pays fourni par la source)

Denosumab and pembrolizumab in clear cell renal carcinoma (KEYPAD): A phase II trial (ANZUP1601).

Craig Gedye, Abhishek Joshi, Alison Yan Zhang, Andrew Martin et autres

au, nz (code pays fourni par la source)

P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs).

Shalini Subramaniam, Guy C. Toner, Martin R. Stockler, Andrew Martin et autres

au, us, nz, gb (code pays fourni par la source)

Exploring the role for FDG-PET/CT in testicular seminoma at diagnosis and during active surveillance across the disease spectrum

Ciara Conduit, Thuan Tzen Koh, Michael F Hofman, Jeremy Lewin et autres